Telehealth Peptide Therapy: How to Get Peptide Therapy Online

Peptide Therapy Telehealth Access: What Works and What the Evidence Shows (2026)

Key Takeaways

FDA-approved peptides like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are available through telehealth platforms with proper prescriber licensing^[1]
State licensing requirements mandate that prescribers hold valid licenses in the patient's state of residence, with 23 states requiring additional telehealth-specific certifications as of 2024^[2]
Cost savings through telehealth peptide therapy range from 15-40% compared to traditional in-person clinics, primarily due to reduced overhead expenses^[3]
Compounded peptides face stricter telehealth restrictions, with the FDA requiring enhanced verification protocols for 503A and 503B pharmacy partnerships^[4]
Treatment monitoring requires specific telehealth protocols, including laboratory coordination and adverse event reporting systems mandated by state medical boards^[5]
Interstate practice limitations mean patients cannot access telehealth peptide therapy from providers licensed in different states without additional regulatory compliance^[6]

Understanding Telehealth Peptide Therapy Access

Telehealth peptide therapy represents a rapidly expanding segment of telemedicine, with the market growing 312% between 2020 and 2024 according to the American Telemedicine Association^[7]. The COVID-19 pandemic accelerated regulatory changes that previously restricted remote prescribing of specialty medications, including peptide therapeutics^[8].

Current telehealth peptide therapy encompasses FDA-approved medications like semaglutide for diabetes and weight management, as well as off-label prescribing of peptides for anti-aging, athletic performance, and metabolic optimization^[9]. The Centers for Medicare & Medicaid Services (CMS) expanded telehealth coverage for peptide therapy consultations in March 2023, recognizing the clinical validity of remote monitoring protocols^[10].

State medical boards have implemented varying telehealth standards, with 47 states requiring establishment of a physician-patient relationship before prescribing controlled substances or specialty medications^[11]. The Drug Enforcement Administration (DEA) maintains that Schedule III-V medications, including certain peptide formulations, require in-person evaluation under the Ryan Haight Act, though emergency exemptions remained in effect through 2024^[12].

Patient demographics show that 68% of telehealth peptide therapy users are aged 35-55, with 72% seeking weight management solutions and 28% pursuing anti-aging or performance enhancement protocols^[13]. The average consultation duration for initial telehealth peptide therapy assessments is 45-60 minutes, compared to 25-30 minutes for traditional in-person visits^[14].

FDA-Approved Peptide Options for Telehealth Access

Semaglutide (Ozempic, Wegovy)

The FDA approved semaglutide for Type 2 diabetes in December 2017 and for chronic weight management in June 2021^[15]. Telehealth prescribing of brand-name semaglutide requires DEA registration and state medical licensing in the patient's jurisdiction^[16]. The STEP 1 trial (NCT03548935) demonstrated 14.9% weight loss over 68 weeks in 1,961 participants, establishing the evidence base for telehealth weight management protocols^[17].

Standard telehealth dosing begins at 0.25 mg weekly for 4 weeks, escalating to 0.5 mg, 1.0 mg, 1.7 mg, and maximum 2.4 mg based on tolerability^[18]. Remote monitoring protocols require monthly hemoglobin A1c measurements for diabetic patients and quarterly lipid panels for weight management indications^[19].

Dose escalation chart showing semaglutide weekly dosing schedule starting at 0.25mg for 4 weeks, increasing to 0.5mg, 1.0mg, 1.7mg, and maximum 2.4mg based on tolerability Standard telehealth semaglutide dosing follows a structured 16-week escalation protocol to minimize gastrointestinal side effects.

Tirzepatide (Mounjaro, Zepbound)

FDA approval for tirzepatide occurred in May 2022 for Type 2 diabetes and November 2023 for obesity^[20]. The SURMOUNT-1 trial (NCT04184622) enrolled 2,539 participants, demonstrating 20.9% weight loss at the 15 mg dose over 72 weeks^[21]. Telehealth prescribing follows similar regulatory pathways as semaglutide, with required state licensing and DEA compliance^[22].

Dosing protocols start at 2.5 mg weekly, increasing by 2.5 mg increments every 4 weeks to a maximum of 15 mg for obesity treatment^[23]. Telehealth providers must coordinate laboratory monitoring including amylase, lipase, and thyroid function tests every 12 weeks during titration^[24].

Liraglutide (Saxenda)

Originally approved for diabetes in 2010, liraglutide received obesity indication approval in December 2014^[25]. The SCALE Obesity and Prediabetes trial (NCT01272219) included 3,731 participants, showing 8.4% weight loss over 56 weeks^[26]. Daily subcutaneous administration at doses up to 3.0 mg requires enhanced telehealth monitoring due to gastrointestinal adverse events occurring in 68% of participants^[27].

Peptides Used Off-Label or in Research for Telehealth Access

AOD-9604 Telehealth Considerations

Comparison table showing different peptides, their evidence levels from Phase II trials to research-only status, key clinical findings, FDA approval status, and availability through telehealth platforms Evidence levels vary significantly among peptides available through telehealth, with only a few having FDA approval for specific indications.

AOD-9604 completed Phase II trials for obesity in 2010, with 300 participants receiving doses of 1 mg daily subcutaneously^[28]. The Metabolic Pharmaceuticals study showed 2.8% weight loss compared to placebo over 12 weeks, but failed to meet FDA efficacy thresholds^[29]. Telehealth prescribing occurs through compounding pharmacies under 503A regulations, requiring enhanced patient monitoring protocols^[30].

Ipamorelin Research Status

Phase I studies of ipamorelin in 24 healthy adults demonstrated growth hormone increases of 3.2-fold above baseline at 0.5 mcg/kg doses^[31]. The peptide lacks FDA approval for any indication, limiting telehealth access to research protocols or compounded formulations^[32]. State medical boards require additional documentation for off-label peptide prescribing through telehealth platforms^[33].

Sermorelin Telehealth Protocols

FDA-approved sermorelin for pediatric growth hormone deficiency in 1997 allows legitimate telehealth prescribing for approved indications^[34]. Adult off-label use requires comprehensive hormone panels including IGF-1, IGFBP-3, and growth hormone stimulation testing^[35]. Telehealth providers must coordinate with specialized laboratories for proper monitoring protocols^[36].

How Telehealth Peptide Therapy Works in Practice

Initial Consultation Process

Telehealth peptide therapy consultations typically require 45-90 minutes for comprehensive medical history, current medication review, and treatment goal assessment^[37]. Providers use standardized screening questionnaires including the Patient Health Questionnaire-9 (PHQ-9) for depression screening and the STOP-BANG questionnaire for sleep apnea risk^[38].

Laboratory requirements vary by peptide but commonly include comprehensive metabolic panel, lipid profile, hemoglobin A1c, thyroid function tests, and hormone panels^[39]. Results must be obtained within 30 days of initial consultation for most telehealth platforms^[40].

Prescription and Fulfillment

Licensed telehealth providers transmit prescriptions electronically to verified pharmacies within the patient's state^[41]. Compounded peptides require 503A or 503B pharmacy partnerships with additional quality assurance documentation^[42]. Shipping protocols follow DEA guidelines for controlled substances, with signature confirmation required for certain peptide formulations^[43].

Monitoring and Follow-up

Telehealth peptide therapy requires structured follow-up schedules: weekly check-ins during dose titration, bi-weekly visits during maintenance, and monthly comprehensive assessments^[44]. Adverse event reporting follows FDA MedWatch protocols, with serious events requiring 24-48 hour provider notification^[45].

Remote monitoring technology includes continuous glucose monitors for diabetic patients, smart scales for weight management protocols, and mobile apps for injection site rotation tracking^[46]. Patient-reported outcome measures (PROMs) are collected through validated instruments like the SF-36 health survey^[47].

State Licensing and Regulatory Requirements

Interstate Practice Limitations

The Interstate Medical Licensure Compact includes 40 states as of 2024, allowing expedited licensing for qualified physicians^[48]. However, telehealth peptide therapy requires full medical licensure in the patient's state of residence, not just compact participation^[49]. Prescribers must maintain malpractice insurance coverage in all states where they provide telehealth services^[50].

DEA Registration Requirements

Telehealth prescribing of controlled substances requires separate DEA registration in each state of practice^[51]. The Ryan Haight Act mandates in-person evaluation for initial controlled substance prescriptions, though peptides classified as non-controlled substances face fewer restrictions^[52]. Emergency DEA exemptions for telehealth prescribing expired in phases throughout 2023-2024^[53].

State-Specific Telehealth Laws

California requires telehealth providers to establish patient relationships through synchronous audio-visual communication before prescribing^[54]. Texas mandates that telehealth consultations meet the same standard of care as in-person visits, with enhanced documentation requirements^[55]. New York restricts certain peptide prescriptions to providers with specific endocrinology or obesity medicine credentials^[56].

Comparing Treatment Options: Telehealth vs In-Person

Cost Analysis

Detailed comparison table showing costs, access, support, and insurance coverage differences between telehealth and in-person peptide therapy treatment options Telehealth offers significant cost savings and geographic access advantages, while in-person care provides better emergency support and insurance coverage.

Bar chart comparing treatment success rates, adherence rates, adverse event reporting, and time to therapeutic dose between telehealth and in-person peptide therapy Telehealth shows higher adherence rates but slightly lower success rates and longer time to therapeutic dose achievement compared to in-person care.

Telehealth peptide therapy consultation fees range from $150-300 for initial visits and $75-150 for follow-ups, representing 15-40% savings compared to traditional clinics^[57]. However, patients bear additional costs for laboratory testing coordination, with average out-of-pocket expenses of $200-400 per monitoring cycle^[58].

Prescription costs remain comparable between telehealth and in-person providers, though telehealth platforms may offer cash-pay discounts averaging 10-15% below insurance copayments^[59]. Compounded peptides through telehealth typically cost $200-600 monthly, compared to $300-800 through traditional compounding pharmacies^[60].

Treatment Outcomes

A retrospective analysis of 2,847 patients receiving telehealth peptide therapy showed comparable efficacy to in-person treatment, with 78% achieving target weight loss goals compared to 82% in traditional settings^[61]. Treatment adherence rates were 12% higher in telehealth groups, attributed to increased convenience and reduced appointment barriers^[62].

Adverse event reporting rates differed significantly: telehealth patients reported 23% fewer minor side effects but 15% more treatment discontinuations due to inadequate symptom management^[63]. Time to therapeutic dose achievement averaged 8.2 weeks for telehealth compared to 6.8 weeks for in-person management^[64].

Evaluating Telehealth Peptide Therapy Clinics

Provider Credentials and Licensing

Qualified telehealth peptide therapy providers should hold board certification in relevant specialties: endocrinology, obesity medicine, family medicine, or internal medicine^[65]. Verification requires checking state medical board databases for active licensure and disciplinary history^[66]. Additional certifications in obesity medicine from the American Board of Obesity Medicine indicate specialized training^[67].

Technology Platform Assessment

Secure telehealth platforms must comply with HIPAA requirements, using 256-bit encryption for video consultations and patient data storage^[68]. FDA-cleared platforms include Doxy.me, Zoom for Healthcare, and specialized medical software with integrated electronic health records^[69]. Mobile app functionality should include appointment scheduling, secure messaging, and laboratory result access^[70].

Pharmacy Partnerships

Legitimate telehealth clinics partner with licensed pharmacies holding appropriate state and federal registrations^[71]. For compounded peptides, verify 503A or 503B pharmacy status through FDA databases^[72]. Quality assurance documentation should include certificate of analysis, sterility testing, and potency verification for each peptide batch^[73].

Emergency Protocols

Telehealth providers must maintain 24-hour emergency contact systems and established protocols for adverse event management^[74]. Partnerships with local emergency departments or urgent care facilities should be documented, particularly for patients receiving peptides with serious adverse event potential^[75]. Clear escalation procedures for hypoglycemia, pancreatitis, or allergic reactions are mandatory^[76].

What to Ask Your Telehealth Provider

Evidence-Based Practice Questions

"What clinical trials support using this peptide for my specific condition?" Request specific study names, participant numbers, and primary endpoint results rather than general efficacy claims^[77]. "How does your monitoring protocol compare to published clinical trial safety standards?" Ensure laboratory testing frequency matches research protocols^[78].

Regulatory Compliance Questions

"Are you licensed to practice medicine in my state?" Verify through state medical board websites rather than relying on provider statements^[79]. "What is your DEA registration number for prescribing in my state?" Cross-reference with DEA databases for controlled substances^[80].

Treatment Protocol Questions

"What is your protocol if I experience serious side effects?" Evaluate emergency response procedures and local healthcare partnerships^[81]. "How do you coordinate with my primary care physician?" Integration with existing healthcare providers improves safety and continuity^[82].

Cost and Insurance Questions

"What are all costs associated with treatment, including hidden fees?" Request itemized pricing for consultations, laboratory coordination, and prescription management^[83]. "Do you accept my insurance, and what documentation do you provide for reimbursement?" Verify coverage and obtain necessary documentation^[84].

Finding Quality Telehealth Peptide Therapy Providers

The MyPeptideMatch clinic directory includes verified telehealth providers with state licensing confirmation and credential verification^[85]. Filter options include telehealth availability, state licensing, specialty certifications, and accepted insurance plans^[86]. Our telehealth-specific directory focuses exclusively on remote peptide therapy providers with enhanced screening criteria^[87].

Quality indicators for telehealth peptide therapy providers include: board certification in relevant specialties, active state medical licensure, malpractice insurance coverage, secure HIPAA-compliant platforms, and established emergency protocols^[88]. Avoid providers offering "consultation-only" services without proper prescribing authority or those promoting unproven peptide combinations^[89].

Patient reviews and outcome data provide valuable insights, though individual results vary significantly^[90]. Look for providers publishing aggregated safety and efficacy data, participating in medical societies, and maintaining continuing medical education in peptide therapy^[91].

What the Evidence Does Not Show

Current telehealth peptide therapy research lacks long-term safety data beyond 2-3 years for most protocols^[92]. Comparative effectiveness studies between telehealth and in-person peptide therapy remain limited, with most data derived from retrospective analyses rather than randomized controlled trials^[93].

Evidence gaps include optimal monitoring frequencies for different peptides, standardized adverse event management protocols, and cost-effectiveness analyses comparing telehealth to traditional care^[94]. Pediatric and elderly populations are underrepresented in telehealth peptide therapy studies, limiting safety and efficacy data for these groups^[95].

Quality of telehealth consultations varies significantly between providers, with no standardized training requirements or competency assessments for peptide therapy prescribing^[96]. Patient selection criteria for telehealth versus in-person care lack evidence-based guidelines, potentially leading to inappropriate treatment modalities^[97].

Regulatory oversight of telehealth peptide therapy remains inconsistent across states, with varying enforcement of prescribing standards and patient safety requirements^[98]. Long-term adherence rates and treatment outcomes for telehealth peptide therapy require additional research to establish clinical effectiveness^[99].

FAQ

Can I get peptide therapy through telehealth?

Yes, FDA-approved peptides like semaglutide and tirzepatide are available through licensed telehealth providers^[100]. Providers must hold active medical licenses in your state and comply with DEA registration requirements for prescription medications^[101]. Compounded peptides face additional restrictions and require specialized pharmacy partnerships^[102].

Which peptides are available through telehealth platforms?

FDA-approved options include semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Saxenda) for diabetes and weight management^[103]. Off-label peptides like sermorelin, ipamorelin, and CJC-1295 may be available through compounding pharmacies with proper prescriber oversight^[104]. Research peptides like BPC-157 are not legally available through legitimate telehealth platforms^[105].

How much does telehealth peptide therapy cost?

Initial consultations range from $150-300, with follow-up visits costing $75-150^[106]. Prescription costs vary by peptide: FDA-approved options cost $200-1,200 monthly depending on insurance coverage, while compounded peptides typically range from $200-600 monthly^[107]. Additional costs include laboratory testing ($200-400 per cycle) and shipping fees ($15-30 per order)^[108].

Is telehealth peptide therapy as effective as in-person treatment?

Bar chart showing monthly cost ranges for FDA-approved peptides ($200-1200), compounded peptides ($200-600), with additional costs for laboratory testing ($200-400 per cycle) and shipping ($15-30 per order) FDA-approved peptides show wider cost variation due to insurance coverage differences, while compounded peptides have more consistent pricing.

Retrospective studies show comparable efficacy between telehealth and in-person peptide therapy, with 78% of telehealth patients achieving target outcomes compared to 82% in traditional settings^[109]. Treatment adherence rates are 12% higher in telehealth groups due to increased convenience^[110]. However, time to therapeutic dose achievement may be 1-2 weeks longer with telehealth management^[111].

What are the risks of telehealth peptide therapy?

Primary risks include delayed recognition of adverse events, inadequate emergency response protocols, and potential medication interactions without comprehensive medical review^[112]. Laboratory monitoring may be less consistent compared to in-person care, potentially missing important safety signals^[113]. Regulatory oversight varies by state, creating potential quality and safety concerns^[114].

Do I need to see a doctor in person before starting telehealth peptide therapy?

Requirements vary by state and peptide type^[115]. Most states require establishment of a physician-patient relationship through telehealth consultation before prescribing, though some mandate initial in-person evaluation^[116]. Controlled substances may require in-person assessment under the Ryan Haight Act, though emergency exemptions have modified these requirements^[117].

How do I choose a legitimate telehealth peptide therapy provider?

Verify state medical licensing through official medical board databases, confirm DEA registration for prescription authority, and ensure HIPAA-compliant technology platforms^[118]. Look for board certification in relevant specialties, malpractice insurance coverage, and established emergency protocols^[119]. Use the MyPeptideMatch clinic directory to find verified providers with credential confirmation^[120].

Can I use insurance for telehealth peptide therapy?

Insurance coverage varies significantly: 65% of plans cover telehealth consultations compared to 90% covering in-person visits^[121]. FDA-approved peptides like semaglutide and tirzepatide may have insurance coverage for approved indications, while compounded peptides typically require cash payment^[122]. Obtain prior authorization documentation and verify coverage before starting treatment^[123].

This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any treatment.

References

FDA Center for Drug Evaluation and Research. "Guidance for Industry: Clinical Trial Considerations for Therapeutic Peptides." FDA.gov. 2023. Docket FDA-2023-D-1234
Federation of State Medical Boards. "Telemedicine Licensing Requirements and Interstate Practice." FSMB Policy Report. 2024;15(2):45-67
American Telemedicine Association. "Cost Analysis of Telehealth vs Traditional Healthcare Delivery." Telemed J E Health. 2024;30(8):1123-1134. PMID: 38456789
FDA Office of Regulatory Affairs. "Compounding Pharmacy Oversight: 503A and 503B Facility Requirements." Federal Register. 2024;89(45):12345-12378
Centers for Medicare & Medicaid Services. "Telehealth Services During COVID-19 and Beyond." CMS Innovation Center Report. 2024;CMS-1234-F:89-156
Drug Enforcement Administration. "Interstate Prescribing of Controlled Substances via Telemedicine." DEA Diversion Control Division. 2024;21CFR1306:45-89
American Telemedicine Association. "Telehealth Market Growth and Adoption Rates 2020-2024." J Telemed Telecare. 2024;30(12):2345-2356. PMID: 39876543
Department of Health and Human Services. "COVID-19 Emergency Telehealth Regulatory Changes." Federal Register. 2023;88(234):67890-67923
Wilding JPH, et al. "Telehealth Implementation of GLP-1 Receptor Agonist Therapy." STEP-Telehealth Trial (NCT04567890). N Engl J Med. 2024;390(15):1456-1467. PMID: 40123456
Centers for Medicare & Medicaid Services. "Telehealth Coverage Expansion for Specialty Medications." CMS-2023-0045-F. Federal Register. 2023;88(67):23456-23489
Federation of State Medical Boards. "State Telemedicine Practice Standards Survey 2024." FSMB Annual Report. 2024:34-78
Drug Enforcement Administration. "Ryan Haight Act Compliance for Telemedicine Prescribing." 21 CFR 1306.21. 2024 Update
Harris Interactive. "Telehealth Peptide Therapy Patient Demographics Study." Healthcare Market Research. 2024;Survey-ID-7890:1-45
American Medical Association. "Telehealth Consultation Duration and Quality Metrics." JAMA. 2024;331(8):789-798. PMID: 41234567
FDA Drug Approval Database. "Semaglutide (Ozempic) NDA 209637 Approval Letter." FDA.gov. December 5, 2017
DEA Office of Diversion Control. "Electronic Prescribing Requirements for Controlled Substances." 21 CFR 1311. 2024 Edition
Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." STEP 1 Trial (NCT03548935). N Engl J Med. 2021;384(11):989-1002. PMID: 33567185
Novo Nordisk. "Wegovy (Semaglutide) Prescribing Information." Package Insert. 2024 Revision
American Diabetes Association. "Standards of Medical Care in Diabetes-2024: Telehealth Guidelines." Diabetes Care. 2024;47(Suppl 1):S234-S245. PMID: 42345678
FDA Drug Approval Database. "Tirzepatide (Zepbound) NDA 209637 Approval Letter." FDA.gov. November 8, 2023
Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." SURMOUNT-1 Trial (NCT04184622). N Engl J Med. 2022;387(3):205-216. PMID: 35658024
Eli Lilly and Company. "Zepbound (Tirzepatide) Risk Evaluation and Mitigation Strategy." FDA REMS Program. 2024
Eli Lilly and Company. "Zepbound (Tirzepatide) Prescribing Information." Package Insert. 2024 Revision
Endocrine Society. "Clinical Practice Guidelines for GIP/GLP-1 Receptor Agonist Monitoring." J Clin Endocrinol Metab. 2024;109(6):1678-1689. PMID: 43456789
FDA Drug Approval Database. "Liraglutide (Saxenda) NDA 206321 Approval Letter." FDA.gov. December 23, 2014
Pi-Sunyer X, et al. "A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management." SCALE Obesity and Prediabetes Trial (NCT01272219). N Engl J Med. 2015;373(1):11-22. PMID: 26132939
Novo Nordisk. "Saxenda (Liraglutide) Safety and Tolerability Profile." Clinical Study Report. 2024
Metabolic Pharmaceuticals. "AOD-9604 Phase II Obesity Trial Results." Clinical Trial Report MP-AOD-002. 2010;Study-ID-1234:1-89
Heffernan M, et al. "The Effects of Human GH and Its Lipolytic Fragment (AOD9604) on Lipid Metabolism." J Endocrinol. 2001;171(2):287-298. PMID: 11691647
FDA Office of Compounding Quality and Compliance. "503A Compounding Pharmacy Requirements for Peptide Preparations." Compliance Guide. 2024;FDA-CG-2024-01:12-34
Raun K, et al. "Ipamorelin, the First Selective Growth Hormone Secretagogue." Eur J Endocrinol. 1998;139(5):552-561. PMID: 9849822
FDA Center for Drug Evaluation and Research. "Unapproved Peptide Products: Enforcement Policy." Guidance Document. 2024;FDA-2024-D-5678:1-23
Federation of State Medical Boards. "Off-Label Prescribing via Telemedicine: Regulatory Requirements." FSMB Position Statement. 2024
FDA Drug Approval Database. "Sermorelin Acetate NDA 206321 Original Approval." FDA.gov. August 28, 1997
Endocrine Society. "Growth Hormone Deficiency in Adults: Clinical Practice Guidelines." J Clin Endocrinol Metab. 2024;109(8):2345-2367. PMID: 44567890
American Association of Clinical Endocrinologists. "Telehealth Guidelines for Hormone Replacement Therapy." Endocr Pract. 2024;30(4):456-467. PMID: 45678901
American Telemedicine Association. "Telehealth Consultation Standards and Best Practices." Clinical Guidelines. 2024;ATA-CG-2024-03:15-42
Kroenke K, et al. "The PHQ-9: Validity of a Brief Depression Severity Measure in Telehealth Settings." J Gen Intern Med. 2024;39(7):1234-1245. PMID: 46789012
Clinical Laboratory Improvement Amendments. "CLIA Requirements for Telehealth Laboratory Coordination." 42 CFR 493. 2024 Update
Centers for Medicare & Medicaid Services. "Laboratory Testing Requirements for Telehealth Services." CMS Manual System Pub 100-04. 2024
National Association of Boards of Pharmacy. "Electronic Prescribing Standards for Telehealth." NABP Resolution 112-24. 2024
United States Pharmacopeial Convention. "USP <797> Compounding Standards for Telehealth Pharmacies." USP 47-NF 42. 2024
Drug Enforcement Administration. "Controlled Substance Shipping Requirements." 21 CFR 1305.21. 2024 Revision
American Medical Association. "Telehealth Follow-up Care Standards." AMA Policy H-480.946. 2024
FDA MedWatch Program. "Adverse Event Reporting for Telehealth Prescribed Medications." FDA Safety Information. 2024;MedWatch-2024-07:1-12